Argenta Discovery Ltd
|8/9 Spire Green Centre,
Tel: +44 (0)1279 645645
Fax: +44 (0)1279 645646
Argenta Discovery sets new standards in contract research for pharmaceutical and biotechnology companies. Our unique integrated approach to lead optimisation is based on the highest quality medicinal chemistry, biochemistry and computational techniques.
Further Information: http://www.argentadiscovery.com
Related news from our archive
Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022.
Argenta Discovery Announces Collaboration with Antisoma
Scientists from both organizations will work together to develop improved molecules for Antisoma’s programme of telomere targeting agents.
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
The two programmes under the agreement utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Argenta Announces a Significant Collaboration Milestone in the Development of Improved Bronchodilators for COPD
Argenta in a joint programme with AstraZeneca has nominated the first candidate drug to enter formal development by AZ, triggering a milestone payment to Argenta.